US OptionsDetailed Quotes
VKTX241213C45000
- 1.20
- -3.20-72.73%
15min DelayClose Dec 13 16:00 ET
1.20High1.20Low
1.20Open4.40Pre Close1 Volume2 Open Interest45.00Strike Price120.00Turnover0.00%IV-1.76%PremiumDec 13, 2024Expiry Date2.03Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma26.87Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Viking Therapeutics Stock Discussion
Sign in to post a comment
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
3
1
1
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drug...
+2
1
$Viking Therapeutics (VKTX.US)$ the only thing you need is endurance for this stock!
1
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Viking Therapeutics (VKTX.US)$ Not high enough for me to sell, not low enough for me to buy more...
1
1
$Viking Therapeutics (VKTX.US)$ down now but I'm not concerned. Those in the know, know what's about to happen that'swhy they bought a covered call from me for $100. This pharmaceutical is ready for 🚀 with a new drug on the horizon.
loading...
1
$Viking Therapeutics (VKTX.US)$ don’t worry. VK2809 is enough to support the price of this stock to reach 100 and even higher
3
No comment yet
10xStockPicks OP : This is the correctly edited research report. Previous article has a few typos. Special thanks to Fund manager John for his notes. Please do your own research. I firmly believe ESPR will be a solid bet.